1,665 results on '"Targan, Stephan R."'
Search Results
102. Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn’s disease and leads to impaired CFB cleavage and phagocytosis
103. A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews
104. Potent Inhibition of Cytokine Production from Intestinal Lamina Propria T Cells by Phosphodiesterase-4 Inhibitory Thalidomide Analogues
105. Insights into TL1A and IBD Pathogenesis
106. Introductory Words About TL1A/DR3
107. Familial Expression of Anti-Escherichia coli Outer Membrane Porin C in Relatives of Patients With Crohn’s Disease
108. Case Report: Evidence for Transplacental Transfer of Maternally Administered Infliximab to the Newborn
109. Serologic testing in inflammatory bowel disease: Its value in indeterminate colitis
110. Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications
111. Variants in ZNF365 isoform D are associated with Crohnʼs disease
112. Modeling Intestinal Epithelial Response to Interferon-γ in Induced Pluripotent Stem Cell-Derived Human Intestinal Organoids
113. Pre-pouch Ileitis is Associated with Development of Crohn’s Disease-like Complications and Pouch Failure
114. Su1979 NOVEL ASSOCIATIONS OF ADIPOSE TISSUE (AT) VOLUMETRIC MEASURES WITH CLINICAL, SEROLOGIC, AND GENETIC VARIABLES IN CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC)
115. 761 MEGA-ANALYSIS REVEALS NOVEL GENETIC ASSOCIATIONS WITH EXTRAINTESTINAL MANIFESTATIONS IN IBD
116. Mo1859 CLINICAL, SEROLOGIC, AND GENOMIC PREDICTORS OF RESPONSE TO USTEKINUMAB IN CROHN'S DISEASE
117. Su1952 SEROLOGICAL AND GENETIC MARKERS ARE ASSOCIATED WITH ILEAL POUCH OUTCOMES AFTER ILEAL POUCH ANAL ANASTOMOSIS
118. Sa1886 EARLY VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL RESPONSE IN A “REAL WORLD” PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
119. Su1877 ENRICHMENT OF POST-TRANSLATIONAL MODIFICATIONS IN INFLAMMATORY BOWEL DISEASE
120. Su1097 TL1A-MEDIATED BACTERIAL TRANSCYTOSIS BY A MLCK SPLICING VARIANT CONTRIBUTES TO INFLAMMATORY BOWEL DISEASE
121. Toll-like receptor 7 protects against intestinal inflammation and restricts the development of tissue-resident memory CD8+ T cells
122. Mo1110 INTEGRATING EQTL EVIDENCE AND GWAS SUMMARY STATISTICS TO REFINE KNOWN SIGNALS AND IDENTIFY NOVEL CD GENES USING MENDELIAN RANDOMIZATION
123. 717 NOVEL ASSOCIATIONS OF BRAIN MORPHOMETRY WITH CLINICAL, SEROLOGIC, AND GENETIC VARIABLES IN CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC)
124. 567 TL1A OVEREXPRESSION IN CD PATIENTS AND MICE ALTERS PANETH CELL BIOLOGY AND INTESTINAL MICROBIOTA IN PROMOTING ILEAL INFLAMMATION
125. Mo1111 RNASET2 RISK VARIANT AS A NOVEL BLOOD BASED DIAGNOSTIC FOR DEFINING A SEVERE CD PATIENT POPULATION RESPONSIVE TO DIRECTED RNASET2 THERAPEUTICS
126. Su1951 PRE-POUCH ILEITIS IS A RISK FACTOR FOR CROHN'S DISEASE-LIKE COMPLICATIONS, NEED FOR INVASIVE INTERVENTIONS AND IMMUNOSUPPRESSIVE THERAPY IN UC OR IBD-U PATIENTS AFTER ILEAL-POUCH ANAL ANASTOMOSIS
127. Reduced expression of COVID-19 host receptor,ACE2is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn’s disease
128. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohnʼs disease
129. Future biologic targets for IBD: potentials and pitfalls
130. Multiparameter Analysis of Immunogenetic Mechanisms in Clinical Diagnosis and Management of Inflammatory Bowel Disease
131. Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohnʼs Disease
132. Ulcerative Colitis: Evolving Insights into Pathogenesis
133. Contributors
134. Antibodies to CBir1 Flagellin Define a Unique Response That Is Associated Independently With Complicated Crohn’s Disease
135. Development of a Personalized Intestinal Fibrosis Model Using Human Intestinal Organoids Derived From Induced Pluripotent Stem Cells.
136. Detection of Antisynthetic Mannoside Antibodies (AΣMA) Reveals Heterogeneity in the ASCA Response of Crohnʼs Disease Patients and Contributes to Differential Diagnosis, Stratification, and Prediction
137. Fas activates the JNK pathway in human colonic epithelial cells: lack of direct role in apoptosis
138. Epilogue: Bench to bedside and back to bench
139. Introduction: Inflammatory bowel disease: from bench to bedside
140. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin
141. Preface
142. Current Limitations of IBD Treatment: Where Do We Go from Here?
143. Molecular Approaches to the Role of the Microbiota in Inflammatory Bowel Disease
144. Patients with Inflammatory Bowel Disease Are at Risk for Vaccine-Preventable Illnesses
145. Serum Immune Responses Predict Rapid Disease Progression among Children with Crohnʼs Disease: Immune Responses Predict Disease Progression
146. Immunomodulator therapy in inflammatory bowel disease
147. A short-term study of chimeric monoclonal antibody to cA2 to tumor necrosis factor alpha for Crohn's disease
148. Defects in mucosal immunity leading to ulcerative colitis
149. Safety and Efficacy of Adalimumab (D2E7) in Crohnʼs Disease Patients with an Attenuated Response to Infliximab
150. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.